Clarus Therapeutics (BLUW) Income Statement (2025 - 2026)
Income Statement report data from Mar 31, 2025 to Mar 31, 2026 for Clarus Therapeutics (BLUW).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | |
|---|---|---|---|---|---|
Operating Expenses | |||||
Selling General And Administrative | 330K (-28.26%) | 460K (+170.59%) | 170K (+54.55%) | 110K (+37.50%) | 80K |
Operating Expenses | 350K (-32.69%) | 520K (+23.81%) | 420K (+281.82%) | 110K (+37.50%) | 80K |
Operating Income | |||||
Operating Income | -350.00K (-32.69%) | -520.00K (+23.81%) | -420.00K (+281.82%) | -110.00K (+37.50%) | -80.00K |
EBITDA | -330.00K (-36.54%) | -520.00K (+23.81%) | -420.00K (+281.82%) | -110.00K (+37.50%) | -80.00K |
Other Income / Expenses | |||||
Interest Income | - | - | 2.72M (+385.71%) | 560K | - |
Net Interest Income | - | - | 2.72M (+385.71%) | 560K | - |
Net Income | |||||
Income Before Tax | 1.92M (-4.48%) | 2.01M (-12.23%) | 2.29M (+420.45%) | 440K | -80.00K |
Net Income From Continuing Operations | 1.92M (-4.48%) | 2.01M (-12.23%) | 2.29M (+420.45%) | 440K | -80.00K |
Net Income | 1.92M (-4.48%) | 2.01M (-12.23%) | 2.29M (+420.45%) | 440K | -80.00K |